Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director · See Remarks | August 24, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date August 24, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 488,182 |
Reported balance
After 2026-08-24 transaction · row 1
1 source rowRow 1 · 2026-08-24 · Sale · Disposed 13,818 · Balance 488,182 F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2020 Filed Nov 5, 2020 02:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,406 | $139.13 | $195,621.70 |
DisclosureSEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $138.77 to $139.67. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 02:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,146 | $138.06 | $158,211.72 |
DisclosureSEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,906 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $137.77 to $138.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 02:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,940 | $136.98 | $265,739.07 |
DisclosureSEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,052 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $136.77 to $137.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 02:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 13,242 | $136.11 | $1,802,376.57 |
DisclosureSEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,992 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $135.75 to $136.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 02:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,328 | $135.36 | $450,467.43 |
DisclosureSEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,234 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $134.74 to $135.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 02:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 21,062 | $0.88 | $18,534.56 |
DisclosureSEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 33,750 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-20-053573 · doc4.xml · derivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Class A Common Stock · 33,750 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $126.88 | $50,752.00 |
DisclosureSEC source: 0001209191-20-053573 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 12,645 | $125.98 | $1,593,012.04 |
DisclosureSEC source: 0001209191-20-053573 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,900 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $125.78 to $126.34. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 16,905 | $125.47 | $2,121,092.33 |
DisclosureSEC source: 0001209191-20-053573 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,545 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $124.78 to $125.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,800 | $124.26 | $472,186.86 |
DisclosureSEC source: 0001209191-20-053573 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,450 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $123.77 to $124.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 33,750 | $0.88 | $29,700.00 |
DisclosureSEC source: 0001209191-20-053573 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 21:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 6,058 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-20-049519 · doc4.xml · derivative · entry 13 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,250 Underlying: Class A Common Stock · 6,058 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 21:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $114.90 | $11,490.00 |
DisclosureSEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 11 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 21:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 405 | $114.10 | $46,210.01 |
DisclosureSEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 10 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,600 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $113.82 to $114.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 21:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $112.93 | $79,050.09 |
DisclosureSEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 9 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,005 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $112.76 to $113.07. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 21:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,953 | $112.07 | $330,948.03 |
DisclosureSEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,705 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $111.76 to $112.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 21:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,900 | $111.40 | $211,667.03 |
DisclosureSEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,658 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $110.76 to $111.72. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 21:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 6,058 | $0.88 | $5,331.04 |
DisclosureSEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 21:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 27,692 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-20-049519 · doc4.xml · derivative · entry 12 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,308 Underlying: Class A Common Stock · 27,692 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 21:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,648 | $115.34 | $190,082.96 |
DisclosureSEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $115.11 to $115.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 21:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 10,049 | $114.55 | $1,151,099.89 |
DisclosureSEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,148 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $114.07 to $115.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 21:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 12,595 | $113.67 | $1,431,653.50 |
DisclosureSEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,197 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $113.07 to $114.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 21:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,400 | $112.73 | $383,294.24 |
DisclosureSEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,792 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $112.07 to $113.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 21:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 27,692 | $0.88 | $24,368.96 |
DisclosureSEC source: 0001209191-20-049519 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 33,750 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-20-045149 · doc4.xml · derivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Class A Common Stock · 33,750 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $101.24 | $60,745.98 |
DisclosureSEC source: 0001209191-20-045149 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $101.18 to $101.32. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,100 | $100.52 | $211,095.99 |
DisclosureSEC source: 0001209191-20-045149 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,100 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $100.06 to $101.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 25,054 | $99.33 | $2,488,668.94 |
DisclosureSEC source: 0001209191-20-045149 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,200 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $99.03 to $100.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,996 | $98.76 | $592,176.35 |
DisclosureSEC source: 0001209191-20-045149 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,254 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $98.025 to $99.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 33,750 | $0.88 | $29,700.00 |
DisclosureSEC source: 0001209191-20-045149 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| July 01, 2020 Filed Jul 3, 2020 00:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 33,750 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-20-040741 · doc4.xml · derivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,750 Underlying: Class A Common Stock · 33,750 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 01, 2020 Filed Jul 3, 2020 00:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,211 | $88.67 | $107,379.37 |
DisclosureSEC source: 0001209191-20-040741 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $88.50 to $88.875. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2020 Filed Jul 3, 2020 00:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 18,065 | $87.92 | $1,588,354.29 |
DisclosureSEC source: 0001209191-20-040741 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,711 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from 87.50 to $88.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2020 Filed Jul 3, 2020 00:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 14,474 | $87.11 | $1,260,873.56 |
DisclosureSEC source: 0001209191-20-040741 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,776 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $86.50 to $87.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2020 Filed Jul 3, 2020 00:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 33,750 | $0.88 | $29,700.00 |
DisclosureSEC source: 0001209191-20-040741 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 33,750 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-20-034164 · doc4.xml · derivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,500 Underlying: Class A Common Stock · 33,750 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,552 | $81.86 | $454,463.96 |
DisclosureSEC source: 0001209191-20-034164 · doc4.xml · nonDerivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $81.65 to $82.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,600 | $81.30 | $699,191.18 |
DisclosureSEC source: 0001209191-20-034164 · doc4.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,052 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $80.65 to $81.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,800 | $79.99 | $383,928.48 |
DisclosureSEC source: 0001209191-20-034164 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,652 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $79.65 to $80.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,700 | $79.15 | $372,019.10 |
DisclosureSEC source: 0001209191-20-034164 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,452 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $78.65 to $79.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,000 | $78.07 | $546,459.90 |
DisclosureSEC source: 0001209191-20-034164 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,152 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $77.59 to $78.57. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,098 | $77.12 | $238,911.25 |
DisclosureSEC source: 0001209191-20-034164 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,152 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.595 to $77.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:55 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 33,750 | $0.88 | $29,700.00 |
DisclosureSEC source: 0001209191-20-034164 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 33,750 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-20-027170 · doc4.xml · derivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,250 Underlying: Class A Common Stock · 33,750 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,120 | $79.20 | $88,704.78 |
DisclosureSEC source: 0001209191-20-027170 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $79.09 to $79.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,116 | $78.59 | $637,822.64 |
DisclosureSEC source: 0001209191-20-027170 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,620 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $78.06 to $79.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,394 | $77.53 | $573,241.29 |
DisclosureSEC source: 0001209191-20-027170 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,736 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $77.065 to $78.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 17,120 | $76.62 | $1,311,718.99 |
DisclosureSEC source: 0001209191-20-027170 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,130 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.06 to $77.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 33,750 | $0.88 | $29,700.00 |
DisclosureSEC source: 0001209191-20-027170 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.